REGENERON PHARMACEUTICALS, INC. (REGN)

569.14 -0.03 (-0.01%)

As of 2025-10-16 21:54:03 EST

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

Traded asNasdaq: REGN
ISINUS75886F1075
CIK0000872589
LEI549300RCBFWIRX3HYQ56
EIN133444607
SectorPharmaceuticals
IndustryPharmaceutical Preparations
CEOLeonard Schleifer
Employees15,106
Fiscal Year End1231
Address777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591
Phone9148477000
Websitehttps://www.regeneron.com/
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
REGNREGENERON PHARMACEUTICALS, INC.2025-10-16 21:54:03569.14-0.03-0.01
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
REGN0000872589REGENERON PHARMACEUTICALS, INC.US75886F1075549300RCBFWIRX3HYQ56133444607Nasdaq2834Pharmaceutical Preparations1231NY777 OLD SAW MILL RIVER ROADTARRYTOWNNY10591UNITED STATESUS9148477000777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591REGENERON PHARMACEUTICALS INCPharmaceuticals1988Leonard Schleifer15,106https://www.regeneron.com/113,800,000,00094,410,42393,955,110Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.2025-10-10 19:13:50
This is a preview of the latest data. Subscribe to access the full data.
REGN Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
REGN Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2024113,800,000,00037,100,000,00048.3703———
202376,700,000,00014,700,000,00023.7097———
202262,000,000,0004,935,000,0008.648———
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Board CoChair, Chief Executive Officer, President20221,811,995—04,131,3491,060,7257,004,069
Board CoChair, Chief Executive Officer, President20211,767,800—04,030,584672,1306,470,514
George D. YancopoulosChief Scientific Officer, President20191,170,500—4,983,2262,598,5102,123,13520,664,135
Robert E. LandryChief Financial Officer, Executive Vice President2019730,000—2,840,008811,395234,7067,931,542
Leonard S. SchleiferChief Executive Officer, President20191,377,100—4,983,2263,057,1623,380,43421,455,117
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202415,106
202313,450
202211,851
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue14,202,000,00013,117,200,00012,172,900,000
Cost Of Revenue1,087,300,000932,100,000800,000,000
Gross Profit———
Research And Development Expenses5,132,000,0004,439,000,0003,592,500,000
General And Administrative Expenses2,954,400,0002,631,300,0002,115,900,000
Operating Expenses10,211,300,0009,070,100,0007,434,000,000
Operating Income3,990,700,0004,047,100,0004,738,900,000
Net Income4,412,600,0003,953,600,0004,338,400,000
Earnings Per Share Basic40.937.0540.51
Earnings Per Share Diluted38.3434.7738.22
Weighted Average Shares Outstanding Basic107,900,000106,700,000107,100,000
Weighted Average Shares Outstanding Diluted115,100,000113,700,000113,500,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents2,488,200,0002,730,000,0003,105,900,000
Marketable Securities Current6,524,300,0008,114,800,0004,636,400,000
Accounts Receivable6,211,900,0005,667,300,0005,328,700,000
Inventories3,087,300,0002,580,500,0002,401,900,000
Non Trade Receivables———
Other Assets Current———
Total Assets Current18,660,900,00019,479,200,00015,884,100,000
Marketable Securities Non Current8,900,100,0005,396,500,0006,591,800,000
Property Plant And Equipment———
Other Assets Non Current1,136,000,000444,100,000336,400,000
Total Assets Non Current19,098,500,00013,601,000,00013,330,400,000
Total Assets37,759,400,00033,080,200,00029,214,500,000
Accounts Payable789,500,000606,600,000589,200,000
Deferred Revenue627,700,000458,900,000477,900,000
Short Term Debt———
Other Liabilities Current——0
Total Liabilities Current3,944,300,0003,423,400,0003,141,300,000
Long Term Debt1,984,400,0001,982,900,0001,981,400,000
Other Liabilities Non Current1,571,400,000854,100,000638,000,000
Total Liabilities Non Current4,461,500,0003,683,700,0003,409,200,000
Total Liabilities8,405,800,0007,107,100,0006,550,500,000
Common Stock000
Retained Earnings31,672,900,00027,260,300,00023,306,700,000
Accumulated Other Comprehensive Income-7,900,000-80,900,000-238,800,000
Total Shareholders Equity29,353,600,00025,973,100,00022,664,000,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization482,900,000421,000,000341,400,000
Share Based Compensation Expense982,800,000885,000,000725,000,000
Other Non Cash Income Expense-23,500,000100,000-368,000,000
Change In Accounts Receivable554,000,000338,800,000-707,800,000
Change In Inventories619,700,000271,700,000696,500,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable735,100,000598,600,000-138,400,000
Change In Other Liabilities———
Cash From Operating Activities4,420,500,0004,594,000,0005,014,900,000
Purchases Of Marketable Securities16,617,400,00011,646,000,0007,487,900,000
Sales Of Marketable Securities15,027,300,0009,442,200,0005,550,500,000
Acquisition Of Property Plant And Equipment755,900,000718,600,000590,100,000
Acquisition Of Business16,500,00054,900,000—
Other Investing Activities———
Cash From Investing Activities-2,468,100,000-3,185,100,000-3,784,600,000
Tax Withholding For Share Based Compensation1,029,100,000700,600,000445,700,000
Payments Of Dividends———
Issuance Of Common Stock1,465,300,0001,145,500,0001,519,500,000
Repurchase Of Common Stock2,613,900,0002,214,600,0002,099,800,000
Issuance Of Long Term Debt——0
Repayment Of Long Term Debt———
Other Financing Activities-33,400,000——
Cash From Financing Activities-2,200,500,000-1,790,100,000-1,009,000,000
Change In Cash-248,800,000-381,600,000221,300,000
Cash At End Of Period2,488,200,0002,730,000,0003,105,900,000
Income Taxes Paid743,000,000870,300,0001,502,400,000
Interest Paid52,600,00073,100,00053,700,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share40.937.0540.51
Price To Earnings Ratio17.416423.705517.8102
Earnings Growth Rate10.3914-8.5411-46.9764
Price Earnings To Growth Ratio1.676-2.7755-0.3791
Book Value Per Share272.0445243.4217211.6153
Price To Book Ratio2.61843.60813.4094
Ebitda5,693,700,0005,317,900,0006,241,600,000
Enterprise Value76,356,607,00092,966,443,00076,147,079,000
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.06760.07630.0874
Capital Expenditures———
Free Cash Flow———
Return On Equity0.15030.15220.1914
One Year Beta0.7240.50930.582
Three Year Beta0.58370.59590.5812
Five Year Beta0.5830.60730.672
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
SING GEORGE LDirector2025-01-02166A27,828
SING GEORGE LDirector2025-01-021,958A1,958
Bassler Bonnie LDirector2025-01-02166A1,548
Bassler Bonnie LDirector2025-01-021,958A1,958
BROWN MICHAEL SDirector2025-01-02166A1,548
This is a preview of the latest data. Subscribe to access the full data.
Senate Trading
Name Of Reporting PersonType Of Reporting PersonReport DateTransaction TypeTransaction DateOwner TypeAmount
Thomas H TubervilleSenator2024-05-15Sale (Full)2024-04-04Joint$1,001 - $15,000
Thomas H TubervilleSenator2023-05-12Purchase2023-04-03Joint$1,001 - $15,000
Thomas H TubervilleSenator2023-05-11Purchase2023-04-03Joint$1,001 - $15,000
Thomas H TubervilleSenator2022-04-08Sale (Full)2022-03-30Joint$1,001 - $15,000
Thomas H TubervilleSenator2021-07-23Purchase2021-03-29Joint$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Rob Bresnahan2025-06-09PA08Purchase2025-05-15—$1,001 - $15,000
Byron Donalds2025-05-24FL19Sale2025-04-10Spouse$1,001 - $15,000
Byron Donalds2025-05-24FL19Sale2025-04-10—$1,001 - $15,000
Julie Johnson2025-05-14TX32Sale2025-04-01Joint$1,001 - $15,000
Jefferson Shreve2025-05-08IN06Sale2025-04-07—$15,001 - $50,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
WILLNER & HELLER, LLC2025-09-30212,840379561.5831
Mezzasalma Advisors, LLC2025-09-301,405,6752,500562.27
GREENWOOD CAPITAL ASSOCIATES LLC2025-09-307,079,54212,591562.27
MEYER HANDELMAN CO2025-09-301,608,0922,860562.2699
HALBERT HARGROVE GLOBAL ADVISORS, LLC2025-09-302,2504562.5
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
ETF Series Solutions2025-07-31Aptus Large Cap Enhanced Yield ETFDUBS382208,365.720.0871
Pacer Funds Trust2025-07-31Pacer US Export Leaders ETFPEXL615335,457.90.9612
Pacer Funds Trust2025-07-31Pacer Trendpilot US Large Cap ETFPTLC6,5303,561,853.80.1067
Pacer Funds Trust2025-07-31Pacer US Cash Cows 100 ETFCOWZ407,217222,120,584.821.1185
Pacer Funds Trust2025-07-31Pacer S&P 500 Quality FCF Aristocrats ETFLCOW10255,636.920.4575
This is a preview of the latest data. Subscribe to access the full data.